🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

197 results for “Keytruda” Clear

  1. PACLITAXEL , Lenvatinib, MK-4830, FAMOTIDINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PARACETAMOL , IRINOTECAN , -, Lenvatinib, -, MK-2870

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  2. PACLITAXEL ALBUMIN-BOUND, PACLITAXEL , DOCETAXEL , Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion., mRNA-4157, CARBOPLATIN

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  3. PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  4. Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  5. Padcev 30 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Padcev 20 mg powder for concentrate for solution for infusion

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  6. Pembrolizumab (KEYTRUDA®) and PDS0101

    PDS Biotechnology Corp

    Metastatic Head and Neck Cancer

    phase 2 other completed

    1 trial

  7. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, BI 1810631, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Boehringer Ingelheim

    locally advanced or metastatic NSCLC

    phase 2 small molecule active

    1 trial

  8. Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin-Teva 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Pemetrexed Pfizer 100 mg powder for concentrate for solution for infusion, JEMPERLI 500 mg concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion., Pemetrexed Pfizer 25 mg/ml concentrate for solution for infusion.

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  9. Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion, mRNA-4157

    Merck Sharp and Dohme

    Melanoma

    phase 2 small molecule active

    1 trial

  10. TRETINOIN, gebasaxturev, MK-4280A, vibostolimab, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage IIIB or IIIC or IIID melanoma

    phase 2 small molecule active

    1 trial

  11. Temodal 140 mg hard capsules, Temodal 100 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 140 mg hard capsules, Temodal 180 mg hard capsules, Temodal 100 mg hard capsules, Temodal 5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NOX-A12, Temodal 250 mg hard capsules, MVASI 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., Temodal 20 mg hard capsules, Temodal 250 mg hard capsules, Temodal 180

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 2 small molecule active

    1 trial

  12. TransCon IL-2 ß/ү, TransCon TLR7/8 Agonist, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    phase 2 small molecule active

    1 trial

  13. TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial

  14. Trodelvy 200 mg powder for concentrate for solution for infusion, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  15. Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. YERVOY 5 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion, DACARBAZINE

    Immunocore Ireland Limited

    Previously untreated advanced uveal melanoma (UM)

    phase 2 small molecule active

    1 trial

  17. Zercepac 150 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    cholangiocarcinoma or gallbladder carcinoma

    phase 2 small molecule active

    1 trial

  18. evorpacept, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    metastatic or unresectable, recurrent HNSCC

    phase 2 small molecule active

    1 trial

  19. favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  20. rolistobart, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL , CARBOPLATIN , MK-4830, MK-4830, PEMETREXED , boserolimab, vibostolimab

    Merck Sharp and Dohme

    non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  21. rolistobart, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  22. rolistobart, boserolimab, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma

    Celltrion Healthcare Australia Pty Ltd

    Completely Resected Stage IIB, IIC, and III Melanoma

    phase 1 other active

    1 trial

  24. Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients

    Formycon AG

    Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources